Bill
Bill > SB2384
ND SB2384
ND SB2384A BILL for an Act to provide for a legislative management study relating to vaccines for respiratory syncytial virus and vaccines developed using messenger ribonucleic acid technology.
summary
Introduced
01/23/2023
01/23/2023
In Committee
04/03/2023
04/03/2023
Crossed Over
02/10/2023
02/10/2023
Passed
Dead
04/29/2023
04/29/2023
Introduced Session
68th Legislative Assembly
Bill Summary
A BILL for an Act to provide for a legislative management study relating to vaccines for respiratory syncytial virus and vaccines developed using messenger ribonucleic acid technology.
AI Summary
This bill directs the North Dakota Legislative Management to study the long-term health effects of vaccines for respiratory syncytial virus (RSV) and vaccines developed using messenger ribonucleic acid (mRNA) technology. The study must include input from the Department of Health and Human Services, an examination of potential health risks, and an analysis of the cost of treatment and diagnostics for individuals who suffer physical injury from these vaccines. The Legislative Management will report its findings and recommendations, along with any necessary legislation, to the 69th Legislative Assembly.
Committee Categories
Government Affairs
Sponsors (4)
Last Action
Second reading, failed to pass, yeas 38 nays 53 (on 04/04/2023)
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.ndlegis.gov/assembly/68-2023/regular/bill-overview/bo2384.html |
| BillText | https://www.ndlegis.gov/assembly/68-2023/regular/documents/23-1082-02000.pdf |
| BillText | https://www.ndlegis.gov/assembly/68-2023/regular/documents/23-1082-01000.pdf |
Loading...